Navigation Links
FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
Date:2/29/2008

pre-existing hypertension or other underlying conditions that might be

compromised by increases in blood pressure. Cases of elevated blood

pressure requiring immediate treatment have been reported.

-- SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding

events. Concomitant use of aspirin, NSAIDs, warfarin, and other

anticoagulants may add to this risk.

-- Mydriasis has been reported in association with PRISTIQ; therefore,

patients with raised intraocular pressure or those at risk of acute

narrow-angle glaucoma (angle-closure glaucoma) should be monitored.

-- As with all antidepressants, PRISTIQ should be used cautiously in

patients with a history or family history of mania or hypomania.

-- Caution is advised in administering PRISTIQ to patients with

cardiovascular, cerebrovascular, or lipid metabolism disorders.

Increases in blood pressure and small increases in heart rate were

observed in clinical studies with PRISTIQ.

-- Dose-related elevations in fasting serum total cholesterol, LDL (low

density lipoprotein) cholesterol, and triglycerides were observed in

clinical studies. Measurement of serum lipids should be considered

during PRISTIQ treatment.

-- Symptoms associated with discontinuation of PRISTIQ have been reported.

Patients should be monitored for symptoms when discontinuing treatment.

A gradual reduction in dose rather than abrupt cessation is recommended

whenever possible.

-- Dosage adjustment (50 mg every other day) is necessary in patients with

severe renal impairment or end-stage renal disease (ESRD). The dose

should not be escalated in patients with moderate or severe renal

impairment or ESRD.

-- Products containing desvenlafaxine and products containing venlafaxine

should not be used concomitantly with PRIST
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

6

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
2. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
3. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
4. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
5. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
6. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
9. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
10. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
11. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... The Conference Forum announced ... Advance Clinical Trials conference taking place on September 19-20 ... , Disruptive thinkers from Novartis, Pfizer, Eli Lilly, ... approaches to reduce expensive infrastructure, engage patients and generate ... be big, or novel, or it must change the ...
(Date:5/22/2013)... 2013  Empire Genomics announced today it has ... novel genomic biomarker from Cornell University for use ... help in diagnosing and determining treatment for patients ... Neuroendocrine prostate cancer (NEPC) is a lethal variant ... novo, but more commonly arises after hormonal therapy ...
(Date:5/22/2013)... CANTON, Mass. and NEW ORLEANS ... commercial leader in the field of regenerative medicine, presented ... expert economists from Analysis Group (a leading health economics ... that diabetic foot ulcers (DFU) and venous leg ulcers ... The results of this research, which reveal annual ...
(Date:5/22/2013)... -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company ... Microcap Conference, May 30, in New York, NY ... , CPA, Chief Financial Officer of Cleveland BioLabs, will present ... 1:30 p.m. Eastern Time.  A live and archived webcast of ... of the Cleveland BioLabs website at www.cbiolabs.com . ...
Breaking Biology Technology:Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2
... 14 Response Genetics, Inc.,(Nasdaq: RGDX ), ... June 30, 2007. "The second quarter of ... our successful initial public offering in June," said,Kathleen ... are very,pleased by the recent developments that have ...
... Year, - 17 Percent Quarter-to-Quarter Revenue Gain Evidences Start of Turnaround ... for Core Business ... - DelSite Signs Additional Agreements, IRVING, Texas, Aug. 14 Carrington,Laboratories, Inc. (Nasdaq: ... compared to $6.5 million in the year ago,period. The revenue in the quarter just ...
... NEW YORK, Aug. 14 Summertime equals fun ... with irritable bowel syndrome (IBS), typical,summer fare could ... Koff, author of "Recipes for IBS," has more ... summer months to prevent IBS from,ruining their celebrations. ...
Cached Biology Technology:Response Genetics Reports Second Quarter 2007 Financial Results 2Response Genetics Reports Second Quarter 2007 Financial Results 3Response Genetics Reports Second Quarter 2007 Financial Results 4Response Genetics Reports Second Quarter 2007 Financial Results 5Response Genetics Reports Second Quarter 2007 Financial Results 6Response Genetics Reports Second Quarter 2007 Financial Results 7Response Genetics Reports Second Quarter 2007 Financial Results 8Carrington Reports Second Quarter 2007 Results 2Carrington Reports Second Quarter 2007 Results 3Carrington Reports Second Quarter 2007 Results 4Carrington Reports Second Quarter 2007 Results 5Carrington Reports Second Quarter 2007 Results 6Carrington Reports Second Quarter 2007 Results 7
(Date:5/22/2013)... join together in a major new effort to educate ... providing Earth,s people with clean water that looms ahead ... comment article in the current edition of Chemical ... American Chemical Society (ACS), the world,s largest scientific society. ... and Jerald L. Schnoor, Ph.D., explain that shortages of ...
(Date:5/22/2013)... is responsible for legionellosis, an infectious disease that can ... pathogen has developed a complex method enabling it to ... avoiding these acting against the infectious bacteria. , Research ... in which teams from the National Institute of Health ... in Barcelona (BSC) have also participated, has described for ...
(Date:5/21/2013)... Biologists have known for a long time that some ... well understood, particularly for plants. But it may be ... Australian National University and the U. S. National Evolutionary ... published 21 May in the journal Nature Communications ... faster-changing genomes. , Drawing from a database of global ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2Small but speedy: Short plants live in the evolutionary fast lane 2
... Accurate duplication of genetic material and the faithful ... initiation of DNA replication is linked both to cell ... other "eukaryotes," the assembly of a multi-protein complex called ... initiation of DNA replication. As the name implies, origin ...
... ,PROVIDENCE, R.I. [Brown University] Seemingly healthy adults, if ... physiological consequences decades later. In research published online last ... led by psychiatrists at Brown University and Butler Hospital ... kids appear to have an elevated inflammatory response to ...
... Mont. -- Invasive plants make life tougher for farmers and ... Missouri River Basin, so why not turn the plants into ... Russian olive and saltcedar alone could supply biomass far into ... Converting invasive plants to fuel is an intriguing idea ...
Cached Biology News:Novel protein critical for cellular proliferation discovered 2Childhood adversity may lead to unhealthy stress response in adult life 2Childhood adversity may lead to unhealthy stress response in adult life 3Montana State, partners in 6 states consider converting invasive plants to fuel 2Montana State, partners in 6 states consider converting invasive plants to fuel 3Montana State, partners in 6 states consider converting invasive plants to fuel 4
Formulation: 10mM PBS/500 mM NaCl, 0.09% NaN3, pH 7.2...
p27 rabbit polyclonal antibody...
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Biology Products: